MKI67 and glioblastoma: Under ALZ003 administration, oncogenic markers, including c-myc, Ki-67 and PCNA, were also obviously decreased in tumor area (Fig. 8F and G), indicating that ALZ003 is a potent and safe compound for glioblastoma therapy.